Trademark: 88322050
Word
VYRASA
Status
Pending
Status Code
734
Status Date
Wednesday, January 19, 2022
Serial Number
88322050
Mark Type
4000
Filing Date
Friday, March 1, 2019
Published for Opposition
Tuesday, May 21, 2019

Trademark Owner History
Allergan Sales, LLC - Owner At Publication

Classifications
5 Pharmaceutical preparations, namely, breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; none of the above relating to pharmaceutical products for the prevention or treatment of cancer

Trademark Events
Jan 20, 2022
Notice Of Approval Of Extension Request E-Mailed
Jan 19, 2022
Sou Extension 5 Granted
Jan 11, 2022
Sou Extension 5 Filed
Jan 19, 2022
Case Assigned To Intent To Use Paralegal
Jan 11, 2022
Teas Extension Received
Jul 14, 2021
Notice Of Approval Of Extension Request E-Mailed
Jul 12, 2021
Sou Extension 4 Granted
Jul 12, 2021
Sou Extension 4 Filed
Jul 12, 2021
Teas Extension Received
Jan 9, 2021
Notice Of Approval Of Extension Request E-Mailed
Jan 7, 2021
Sou Extension 3 Granted
Jan 7, 2021
Sou Extension 3 Filed
Jan 7, 2021
Teas Extension Received
Jun 30, 2020
Notice Of Approval Of Extension Request E-Mailed
Jun 26, 2020
Sou Extension 2 Granted
Jun 26, 2020
Sou Extension 2 Filed
Jun 26, 2020
Teas Extension Received
Jan 11, 2020
Notice Of Approval Of Extension Request E-Mailed
Jan 9, 2020
Sou Extension 1 Granted
Jan 9, 2020
Sou Extension 1 Filed
Jan 9, 2020
Teas Extension Received
Jul 16, 2019
Noa E-Mailed - Sou Required From Applicant
May 21, 2019
Official Gazette Publication Confirmation E-Mailed
May 21, 2019
Published For Opposition
May 1, 2019
Notification Of Notice Of Publication E-Mailed
Apr 11, 2019
Approved For Pub - Principal Register
Apr 9, 2019
Assigned To Examiner
Mar 28, 2019
New Application Office Supplied Data Entered In Tram
Mar 5, 2019
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24